Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + FOLFOX
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib + FOLFOX is a combination regimen used primarily in the treatment of advanced or metastatic colorectal cancer and has also been studied in gastric cancer. Apatinib is a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR-2), thereby inhibiting tumor angiogenesis and promoting apoptosis and autophagy in tumor cells. FOLFOX is a chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. These agents work synergistically to destroy rapidly dividing cancer cells through DNA damage and inhibition of DNA synthesis. The combination aims to enhance antitumor efficacy by targeting both angiogenesis pathways (via apatinib) and cell proliferation pathways (via cytotoxic chemotherapy)[1][3][6].
- Brand names
- Eloxatin
- Other names
- folinic acid + fluorouracil + oxaliplatin
02
Targets
DNAVEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on apatinib + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + FOLFOX.